A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.

NCT05338086 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

558

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Women With Osteoporosis

Interventions

DRUG: MB09 (denosumab biosimilar)
DRUG: EU-Prolia
DIETARY_SUPPLEMENT: Elemental Calcium
DIETARY_SUPPLEMENT: Vitamin D

Sponsor

mAbxience Research S.L.